| Literature DB >> 31277753 |
Abstract
Osteoarthritis is the most common form of arthritis and unfortunately lacks disease-modifying treatments. This has led to a growing demand for more effective nonoperative treatment options. Platelet-rich plasma and mesenchymal stem cell therapy offer the potential to modify the natural course of knee osteoarthritis using cell-based technology. Because of the lack of high-quality evidence and the large degree of heterogeneity, in terms of study designs and measured outcomes, the use of platelet-rich plasma or mesenchymal stem cell therapy to treat knee osteoarthritis cannot be recommended at this time.Entities:
Keywords: Knee osteoarthritis; Meta-analyses; Osteoarthritis; Platelet-rich plasma; Randomized controlled clinical trials; Regenerative medicine; Stem cells
Mesh:
Year: 2019 PMID: 31277753 DOI: 10.1016/j.rdc.2019.04.010
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN: 0889-857X Impact factor: 2.670